Department of Gastroenterological Surgery, University of Helsinki and Helsinki University Hospital, Meilahden Tornisairaala, PO Box 340, 00029, HUS, Helsinki, Finland.
BMC Cancer. 2022 Apr 2;22(1):356. doi: 10.1186/s12885-022-09460-0.
Colorectal cancer (CRC) incidence in Finland has risen steadily. Given development in cancer treatments in recent decades, disease-specific data on the long-term prognosis of patients may be obsolete. Thus, this study aimed to report 5-year disease-specific survival (DSS) and relative survival based on tumour spread and site among CRC patients diagnosed between 1991 and 2015 in Finland.
We conducted a population-based registry study among 59 465 CRC patients identified from the Finnish Cancer Registry.
The 5-year DSS for all CRC patients was 56.7% [95% confidence interval (CI) 56.3-57.1%] for 1991 through 2015. Tumour site-specific survival has improved for the period 2006-2015 versus 1991-2005 for right-sided colon cancer from 54.8% (95% CI 53.8-55.8%) to 59.9% (95% CI 58.7-61.1%), for left-sided colon cancer from 54.1% (95% CI 52.9-55.3%) to 61.0% (95% CI 59.8-62.2%) and for rectal cancer from 53.6% (95% CI 52.2-55.0%) to 62.3% (95% CI 61.3-63.3%). The 5-year relative survival for the period 2006 through 2015 was 93.6% for localised disease (stage I); 84.2% for locally advanced tumour invading adjacent structures (stage II); 68.2% for regional disease with regional lymph node metastases (stage III); and 14.0% for metastatic disease (stage IV).
This study confirms that survival for CRC has improved in recent decades in Finland, mirroring observations from other Western countries. However, the classification of tumour spread within the Finnish Cancer Registry differs slightly from the TNM classification, thereby limiting the generalisability of these results.
芬兰的结直肠癌(CRC)发病率一直在稳步上升。鉴于近几十年来癌症治疗的发展,关于患者长期预后的特定疾病数据可能已经过时。因此,本研究旨在报告芬兰 1991 年至 2015 年间诊断出的 CRC 患者基于肿瘤扩散和部位的 5 年疾病特异性生存率(DSS)和相对生存率。
我们对芬兰癌症登记处确定的 59465 例 CRC 患者进行了一项基于人群的登记研究。
所有 CRC 患者的 5 年 DSS 为 1991 年至 2015 年期间的 56.7%(95%CI 56.3-57.1%)。肿瘤部位特异性生存率在 2006 年至 2015 年期间有所提高,右侧结肠癌从 54.8%(95%CI 53.8-55.8%)提高到 59.9%(95%CI 58.7-61.1%),左侧结肠癌从 54.1%(95%CI 52.9-55.3%)提高到 61.0%(95%CI 59.8-62.2%),直肠癌从 53.6%(95%CI 52.2-55.0%)提高到 62.3%(95%CI 61.3-63.3%)。2006 年至 2015 年期间,局限性疾病(I 期)的 5 年相对生存率为 93.6%;局部侵袭邻近结构的局部进展期肿瘤(II 期)为 84.2%;区域疾病伴区域淋巴结转移(III 期)为 68.2%;转移性疾病(IV 期)为 14.0%。
本研究证实,芬兰近几十年来 CRC 的生存率有所提高,与其他西方国家的观察结果一致。然而,芬兰癌症登记处的肿瘤扩散分类与 TNM 分类略有不同,因此这些结果的通用性有限。